(be-si-flox-a-sin) ,


(trade name)


Therapeutic: anti infectives
Pharmacologic: fluoroquinolones
Pregnancy Category: C


Treatment of bacterial conjunctivitis.


Inhibits bacterial DNA synthesis by inhibiting DNA gyrase.

Therapeutic effects

Death of susceptible bacteria with decreased symptoms and sequelae of bacterial conjunctivitis.
Active against CDC coryneform group G, Corynebacterium pseudodiphtheriticum, Corynebacterium striatum, Haemophilus influenzae, Moraxella lacunata, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus lugdunensis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae and Streptococcus salivarius.


Absorption: Minimal absorption follows ophthalmic use.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: 7 hr.

Time/action profile

Ophthunknownunknown6–12 hr


Contraindicated in: Contact lens use.
Use Cautiously in: Obstetric: Use during pregnancy only if potential benefit justifies potential risk to fetus; Lactation: Use cautiously during lactation; Pediatric: Safe use in children <1 yr not established.

Adverse Reactions/Side Effects

Central nervous system

  • headache

Ear, Eye, Nose, Throat

  • conjunctival redness (most frequent)
  • blurred vision
  • eye irritation
  • eye pain,
  • eye pruritus.


Drug-Drug interaction

None noted.


Ophthalmic (Adults and Children ≥1 yr) One drop in affected eye(s) three times daily (4–12 h apart) for 7 days.


Ophthalmic suspension: 0.6% 5 mL in 7.5 mL bottle

Nursing implications

Nursing assessment

  • Assess eye for signs of infection (swelling, redness, pain, discharge) prior to and periodically during therapy.

Potential Nursing Diagnoses

Risk for infection (Indications)


  • Ophthalmic: Invert closed bottle and shake once before use. Remove cap with bottle still inverted. Tilt head back and, with bottle inverted, gently squeeze bottle to instill 1 drop in affected eye 3 times daily (4–12 hrs apart) for 7 days.

Patient/Family Teaching

  • Instruct patient to use besifloxacin as directed, even if feeling better. Do not skip doses or stop therapy early; may lead to decreased effectiveness and resistant infections. Avoid touching applicator to eye, finger, or other areas; may contaminate. Wash hands prior to instillation.
  • Caution patient to avoid wearing contact lenses during therapy.
  • Advise patient to discontinue immediately and notify health care professional if signs or rash or allergic reaction (hives, difficulty breathing, swelling of throat) occur.

Evaluation/Desired Outcomes

  • Resolution of signs and symptoms of infection.
References in periodicals archive ?
Ocular pharmacokinetics/ pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Ten anti-infectives are available for topical treatment of eye infections (systemic concentrations if known): besifloxacin (Besivance) (0.
15) However, studies supporting the use of antibiotics in secondary care involving selected patients, such as polymixin-bacitracin, azithromycin, besifloxacin, moxifloxacin, ciprofloxacin and norfloxacin, produce a statistically significant and faster improvement in clinical resolution or bacterial eradication compared to placebo.
Topoisomerase Mutations That Are Associated with High-Level Resistance to Earlier Fluoroquinolones in Staphylococcus aureus Have Less Effect on the Antibacterial Activity of Besifloxacin.
Efficacy and safety of besifloxacin ophthalmic suspension 0.
Bepotastine (Bepreve; C), an antihistamine, and besifloxacin (Besivance; C), a quinolone antibiotic, are new ophthalmic products.
The older topical agents ofloxacin and ciprofloxacin have largely been replaced by the newer agents levofloxacin, moxifloxacin, gatifloxacin, and now besifloxacin, which was approved by the U.
Other eye drops in the same class include ciprofloxacin (Ciloxan), ofloxacin (Ocuflox), levofloxacin (Quixin), besifloxacin (Besivance) and gatifloxacin (Zymar).
A Food and Drug Administration advisory panel voted 9-0 that an ophthalmic formulation of besifloxacin, a new fluoroquinolone antibiotic, should be approved for treating bacterial conjunctivitis in people aged 1 year and older.
The FDA approved an ophthalmic formulation of a fluoroquinolone antibiotic, besifloxacin, for treating bacterial conjunctivitis.
The Food and Drug Administration has approved an ophthalmic formulation of a fluoroquinolone antibiotic, besifloxacin, for the treatment of bacterial conjunctivitis.
In the two studies comparing besifloxacin with the vehicle, the rates of resolution in symptoms after 4-6 days were significantly greater among those treated with besifloxacin.